

Remarks/Arguments

Reconsideration of this application, as amended, is respectfully requested.

I. Status of the Claims

Claims 1-19 are pending. Claim 1 is amended to require that R¹ is a sulfonamide of group (2), R⁴-S(O)pN(R⁵)-. Dependent species claim 19 is amended accordingly, to delete the only recited species in which R¹ is not selected from group (2).

II. Rejections Under 35 U.S.C. § 112, First Paragraph

Compound claims 1, 2, 4 and 9-13, and method of treatment claims 15-17, stand rejected under 35 U.S.C. § 112, first paragraph. The Examiner states that the claims are enabled for compounds wherein R¹ is from group (2), R⁴-S(O)pN(R⁵)-, but are not enabled for compounds wherein R¹ is selected from one of groups (1) or (3)-(7).

In response, in order to expedite allowance, claim 1 is amended to limit the claims to compounds wherein R¹ is a sulfonamide of group (2). Applicants reserve the right to pursue the canceled subject matter in a continuing application.

In view of the action taken, it is believed that the rejections under 35 U.S.C. § 112, first paragraph, has been overcome. It is respectfully requested that the rejections be withdrawn.

III. Claim Objections

At page 6 of the office action, the Examiner states that claims 3, 5-8 and 14 are objected to as based on a rejected base claim, but would be allowable if rewritten in independent form. Applicants thank the Examiner for the acknowledgement of allowability of dependent claims 3, 5-8 and 14. In view of the amendment to claim 1, it is believed that all pending claims 1-19 are now in condition for allowance.

IV. Conclusion

In view of the action taken and arguments made, claims 1, 2, 4, 9-13 and 15-17 are enabled by the specification, and all pending claims 1-19 are now in condition for allowance.

Favorable action is earnestly solicited.

Respectfully submitted,

By


John C. Todaro, Reg. No. 36,036
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065
Tel.: (732) 594-0125

Date: August 8, 2007